Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
337
Views
10
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia

Harivenkatesh Natarajana Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India; Correspondence[email protected]
,
Lalit Kumarb Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India;
,
Sameer Bakhshib Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India;
,
Atul Sharmab Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India;
,
Thirumurthy Velpandiand Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
,
Madhulika Kabrac Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India;
,
Ajay Gogiab Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India;
,
Nihar Ranjan Biswasd Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
&
Yogendra Kumar Guptad Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
 show all
Pages 418-425 | Received 22 Jan 2018, Accepted 30 May 2018, Published online: 20 Aug 2018

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Harivenkatesh Natarajan. (2019) Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia. Leukemia & Lymphoma 60:8, pages 2096-2097.
Read now

Articles from other publishers (9)

Xiaoxing Huang, Yiwei Liu, Jie Chen, Heng Zheng, Yufeng Ding & Zheng He. (2023) Therapeutic Drug Monitoring of Imatinib and N ‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study . The Journal of Clinical Pharmacology 63:12, pages 1438-1447.
Crossref
LOKESH BAGARI NAGAPPA & ASHWATHY VARADARAJAN THUNDAKATTIL. (2023) CO-RELATION OF P-GLYCOPROTEIN AND PLASMA IMATINIB IN IMATINIB RESPONDERS AND NON-RESPONDERS PATIENTS WITH CHRONIC MYELOID LEUKAEMIA. International Journal of Applied Pharmaceutics, pages 373-378.
Crossref
Eman El-Khateeb, Rajkumar Chinnadurai, Jokha Al Qassabi, Daniel Scotcher, Adam S. Darwich, Philip A. Kalra & Amin Rostami-Hodjegan. (2023) Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease. Therapeutic Drug Monitoring Publish Ahead of Print.
Crossref
Ahmet Emre Eşkazan. (2022) Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!. Cancer 129:4, pages 643-644.
Crossref
Alaa Sabri, Mervat M. Omran, S.Abdel Azim, Raafat Abdelfattah, Rasha Mahmoud Allam & Samia A. Shouman. (2023) A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients. Drug Research.
Crossref
Fang Cheng, Fang Zeng, Qiang Li, Zheng Cui, Yilin Chen, Weiming Li & Yu Zhang. (2022) Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic‐phase chronic myeloid leukemia. Cancer 128:22, pages 3951-3958.
Crossref
Álvaro Corral Alaejos, Aránzazu Zarzuelo Castañeda, Silvia Jiménez Cabrera, Fermín Sánchez‐Guijo, María José Otero & Jonás Samuel Pérez‐Blanco. (2021) External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. British Journal of Clinical Pharmacology 88:4, pages 1913-1924.
Crossref
Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan & Ahmet Emre Eşkazan. (2021) Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Advances 5:17, pages 3344-3353.
Crossref
Hemant MalhotraJerald Radich & Pat Garcia-Gonzalez. (2019) Meeting the needs of CML patients in resource-poor countries. Hematology 2019:1, pages 433-442.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.